Jiangsu Hansoh Pharmaceutical Co., Ltd.

This study tests a new once-weekly injection, HS-20094, against an existing drug (dulaglutide) for people with type 2 diabetes whose blood sugar is not well controlled by metformin alone or with SGLT2 inhibitors. About 546 adults will receive one of the two treatments for 44 week…

This early-phase study tests a new drug called HS-10504 combined with other treatments for people with advanced non-small cell lung cancer that has worsened after prior therapy. The goal is to find safe doses and see if the combination can shrink tumors or slow the disease. About…

This study tests an investigational injection called HS-20094 in adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. About 204 participants will receive either the drug or a placebo to see if it safely lowers blood sugar over 44 to 52 …

This early-stage study tests the safety of a new drug called HS-20152 in 32 healthy adults aged 18 to 64. Participants receive a single dose of the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is to gather initial s…